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Abstract 
 
Nicole Thompson 
THE RELATIONSHIP BETWEEN THE USE OF HORMONAL CONTRACEPTIVES 
AND LIGAMENTOUS KNEE INJURY IN THE FEMALE COLLEGIATE ATHLETE 
2019-2020 
Leslie Spencer, Ph.D. 
Master of Science in Athletic Training 
Female athletes are three to six times more likely than males to sustain a 
ligamentous knee injury due to hormonal risk factors. Hormones of the menstrual cycle 
have been shown to alter the physiological component of ligamentous structures during 
the three phases of the cycle. Use of hormonal contraceptives (HCs) may influence the 
incidence and severity of ligamentous knee injuries in female athletes. The objective of 
this cross-sectional study was to determine the relationship between HC use and the type 
and severity of ligamentous knee injuries sustained among female collegiate athletes 
using an online survey distributed to NCAA female athletes who experienced a 
ligamentous knee injury during the study time period (n=336). The electronic survey 
assessed demographic information, ligamentous knee injury and menstrual cycle 
characteristics, and HC use. Chi-Square analyses showed significant relationships 
between injury type and severity of injury, and injury type and menstrual cycle phase. 
The majority of respondents sustained ACL injuries, were in the luteal phase of the 
menstrual cycle, and HC users. Of the HC users, there were a greater number of 
respondents who were combined hormonal contraceptive users and oral contraceptive pill 
users. The type of ligamentous knee injury (ACL) impacted the severity of the injury. 
Female athletes were at the greatest risk for ligamentous knee injury in the luteal phase of 
the menstrual cycle. Future work should aim to identify injury prevention programs, 
protective equipment, and HC for decreasing the risk for ligamentous knee injury. 
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Chapter 1 
Introduction to Research 
Literature Review 
 Background. With the passing of Title IX of the United States Educational 
Assistance Act in 1972, there has been a significant increase of female participation in 
athletics.1,2 In 2004, there was a reported 80% increase in female and 20% increase in 
male participation in National Collegiate Athletic Association (NCAA) sports.3 By 2018, 
these percentages increased to 43.8% and 56.2% of female and male student-athletes, 
respectively participating in NCAA sports.4 
In 2007, 182,000 collegiate athletes experienced injuries in the NCAA and this 
number has continued to rise with the increase in sport involvement and continual 
recognition of athletic injuries.3,4 More than half of collegiate injuries occur to the lower 
extremity with the knee and ankle being the most common sites.3 In the general U.S. 
population, there are approximately 250,000, or 1 in 3,000, ACL injuries that occur 
annually.2 There are 60% more injuries that occur in women, with 16% being to the knee, 
compared to men in professional basketball.5 Collegiate female athletes account for 
approximately 67% of all ACL injuries and 69% of non-contact ACL injuries compared 
to their male counterparts, making females 3-6 times more likely than males to sustain an 
ACL injury. 1,6,7,8,9,10 The sports in which females are more likely to suffer an ACL injury 
are basketball, gymnastics, lacrosse, and soccer.11,12 
There are various underlying risk factors that can predispose an athlete to a 
ligamentous knee injury.9,13 The differences between males and females in ligamentous 
knee injury and laxity may be explained by biomechanical, neuromuscular, anatomical, 
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and hormonal risk factors.8,1 Hormonal risk factors that occur during the menstrual cycle 
can increase the susceptibility of non-contact knee injuries in female athletes. 6,8,9,12,14 
The Landing Error Scoring System (LESS) assesses the amount of errors an 
individual obtains from a jump-land movement, with a higher score indicating a greater 
risk for ACL injury.15 Both before and after sport-specific exercise, female athletes have a 
significantly higher score on the LESS compared to males athletes, placing them in a 
high-risk category.15 Compared to collegiate male athletes, female athletes have a 20% 
increase in rotary knee laxity while being assessed on the Lachman test, generalized 
ligamentous laxity, and knee hyperextension.16 For every 1.3 mm increase in anterior 
knee displacement, or ligamentous laxity, the risk of ACL injury increased by a factor of 
four.17 
         Fifty-one percent of female athletes reported that their menstrual cycle had an 
effect on their training and athletic performance, with dysmenorrhea being the most 
common complaint in 60-90% of those who do not use hormonal contraceptives (HCs).18 
Primary dysmenorrhea involves a painful menstruation, nausea, headaches, fatigue, and 
diarrhea.18 Other physical symptoms athletes may experience include stomach cramps, 
back pain, bloating, fatigue, vertigo, discomfort, hot flashes, increased appetite, breast 
soreness, dermatological changes, constipation, heavy bleeding, muscle aches, problems 
with exercising, sore throat, tight neck, and weakness.18 Emotional symptoms may 
include mood changes, irritability, and being flustered.18 All of these can be self-limiting 
factors of performance in female athletes.18 
         Females use HCs for their contraceptive effects and to eliminate negative 
symptoms of the menstrual cycle.6,7 A majority (73.6%) of reproductive age women (17-
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40 years of age) have manipulated their menstrual cycle in the previous year, with special 
events, holidays and convenience being the most common reasons.19 Forty percent of 
competitive athletes have modified their menstrual cycle due to physical activity, 
exercise, or sport convience.19 HCs work in favor for competitive female athletes by 
decreasing the likelihood of missing playing time.19 
Ligamentous knee injury types. Ligamentous knee injuries account for 
approximately 40% of knee injuries. The ligaments of the knee are the primary static 
stabilizers of the knee.20 Knee ligamentous structures most commonly injured are the 
anterior cruciate ligament (ACL), medial collateral ligament (MCL), lateral collateral 
ligament (LCL), and posterior cruciate ligament (PCL).21 
Anterior cruciate ligament. The ACL originates on the anteromedial 
intercondylar eminence of the tibia and courses posteriorly and laterally to attach on the 
medial wall of the lateral femoral condyle.2,22 Its function is to resist anterior translation 
and rotation of the tibia.22 Injuries to the ACL may be the result of a direct contact or non-
contact mechanism to the knee.20 ACL injuries are the most common type of ligamentous 
knee injury with an occurrence of 46-68%.21,23   
Medial collateral ligament. The MCL is comprised of three layers on the medial 
side of the knee and ascends from the distal pes anserine of medial tibia to the medial 
femoral condyle.20,22 Its function is to resist valgus forces placed on the lateral aspect of 
the knee.33 MCL injuries make up 26-29% of ligamentous knee injuries.21,23 
Lateral collateral ligament. The LCL, also referred to as the fibulocollateral 
ligament, extends from the fibular head to the lateral femoral epicondyle to resist varus 
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forces placed on the medial aspect of the knee.20,22 LCL injuries comprise 2-4% of all 
ligamentous knee injuries.21,23 
Posterior cruciate ligament. The PCL originates on the posterior intercondylar 
eminence of the tibia and crosses the ACL in the opposite direction as it courses 
anteriorly and medially to insert on the lateral wall of the medial femoral condyle.22 It 
counteracts the ACL to resist posterior, rotation of the tibia and hyperextension of the 
knee.20,22 Injuries to the PCL are commonly caused by a direct blow to the anterior knee 
while the knee is flexed.33 Similarly to the LCL, the PCL comprises approximately 2-4% 
of ligamentous knee injuries.21,23 
Female endocrinology. The pituitary gland is responsible for the control of the 
menstrual cycle.26 Typically, the cycle length lasts an average of 28 days and it is divided 
into three phases or stages, the follicular phase, ovulatory phase, and luteal phase.25 
Although, the phases may be referred to as alternate names, the timeline of the menstrual 
cycle stays consistent. Female sex hormones associated with the menstrual cycle may 
influence ligamentous knee injury and laxity in female athletes. 7,8,12,24,25, 
         The menstrual cycle. The mean length of the menstrual cycle is 28 days but can 
vary from 23-35 days.25 Slaughterbeck et al8 and Heitz et al12 defined the menstrual cycle 
as the menstrual phase (days 0-5), the follicular phase (days 6-14), and the luteal phase 
(days 15-28).8,12 Wojtys et al25 defined the menstrual cycle as the follicular phase (days 
1-9), the ovulatory phase (days 10-14), and the luteal phase (days 15-28).25 Herzberg et 
al7 defined the menstrual phase as the menstrual phase (days 1-6), the ovulatory phase 
(days 12-14), and the luteal phase (days 20-24).7 For the purpose of this study the 
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menstrual cycle will be operationally defined as the follicular phase (days 1-9), the 
ovulatory phase (days 10-14), and the luteal phase (days 15-end of cycle). 
         Hormone levels throughout menstruation. There is a constant fluctuation of 
hormones through the menstrual cycle. Estradiol and progesterone are at their lowest (60 
mg/day) level with the onset of menses in the follicular phase. 7,8,12, During the ovulatory 
phase, estrogen rises to a secretion rate of 400-900 mg per day in conjunction with the 
increase in luteinizing hormone (LH) and the growth of a dominant 
follicle.8,25,27,  Twenty-four hours before ovulation, or at the onset of the luteal phase, 
estradiol peaks and there is a surge in LH and gonadropins.7,8,25 Estradiol then 
significantly drops off to 300 mg per day, but rises again during this phase of the 
menstrual cycle. In conjunction with estradiol, progesterone peaks in the middle of the 
luteal phase at a secretion rate of 25,000 mg per day in response to increasing levels of 
LH and the development of the corpus luteum.7,8,25,27 If there is an absence in pregnancy 
following ovulation, the follicle ruptures or collapses creating a sudden drop, but then 
spike, in estrogen.7,25,27 In the late-luteal phase, progesterone levels rise again, but then 
decreases, triggering menstruation.7,25,27 
         The menstrual cycle and ligamentous knee injury. Since the menstrual cycle is 
one of the most distinct differences between males and females, it seems logical to 
consider that the increased prevalence of ACL ruptures in females over males could be 
due to this process. Wojtys et al25 assessed which phase of the menstrual cycle was 
associated with female ACL injury over a two-year period.25 Sixty-five women who 
sustained an acute non-contact ACL injury were included in this study. Subjects were 
excluded if they were pregnant, or nonpregnant with a history of irregular or missed 
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menstrual cycles. There were 51 oral contraceptive nonusers and 14 oral contraceptive 
users. Subjects were recruited within the first 24 hours of sustaining their ACL injury. 
Each subject completed a questionnaire inquiring about the date and mechanism of 
injury, the frequency of their athletic participation in the past month, and a detailed 
history of their menstrual cycle including, frequency and regularity, date of the last 
menstrual period, average length of the cycle, and oral contraceptive or hormone 
replacement use. Each subject gave a urine sample within 24 hours of sustaining the 
injury, and within 24 hours of the first day of the onset of their next menstrual cycle. The 
mean of the two urine measurements of estrogen, progesterone, luteinizing hormone 
metabolites and creatinine were recorded for analysis to determine cycle phase when 
sustaining the injury.25 
         The results showed that 15 participants injured their ACL in the follicular phase, 
28 in the ovulatory phase, and 22 in the luteal phase. The oral contraceptive nonuser 
group was more likely to tear their ACL during the ovulatory phase (phase II) over the 
follicular or luteal phases. The oral contraceptive user group was also more likely to 
rupture their ACL during the ovulatory phase, but at a lower expectancy than the oral 
contraceptive nonuser group.  
All three hormone metabolite levels measured by the urine assays were within 
normal clinical ranges during the menstrual cycle. However, these were significantly 
higher on the day of injury in comparison to day-one of the menstrual cycles, although 
the results for each group were not indicated. The significant increase in hormone 
metabolite levels on the day of injury suggests that hormone metabolites may influence 
the susceptibility to ACL injury. The authors concluded that when there is a surge in LH 
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and estrogen during the ovulatory phase, there is an increased risk of ACL injury 
compared to the follicular or luteal phase.25 
         Heitz et al12 studied ACL laxity over the course of the menstrual cycle in active 
females.12 All seven subjects reported a normal menstrual cycle, at least one healthy 
knee, and not taking HCs. Subjects were excluded from the study if they had a Q-angle of 
10° in order to eliminate excessive genu valgum effects on results. The subjects reported 
to the appropriate centers on the day their menses began. Blood draws were taken to 
determine estrogen and progesterone levels, and the KT-2000 knee arthrometer was used 
to assess ACL laxity with 67, 89, and 133 N of force applied. These procedures were 
repeated on days 10, 11, 12, 13, 20, 21, 22, and 23 of the menstrual cycle.12 
         The results showed that there was a significant increase in ACL laxity when 
comparing the follicular phase (phase I) and ovulatory phase (phase II) of the menstrual 
cycle. It is suggested that this change may be due to the peak in estrogen during the 
ovulatory phase. There was also a significant difference in ACL laxity when comparing 
the follicular phase (phase I) and luteal phase (phase III) of the menstrual cycle. This 
change may be due to the peak of progesterone levels during the luteal phase, thereby 
causing the greatest amount of ACL laxity during the luteal phase.25 Although the 
number of study subjects was low (n=7), this evidence suggests that the change of 
hormonal levels throughout the menstrual cycle may cause an increase in the laxity to the 
ACL. 
In a systematic review on the menstrual cycle and contraceptives on ACL injuries 
and laxity, Herzberg et al7 found that female athletes were at the lowest risk for ACL 
injury during the luteal phase (days 20-24) of the menstrual cycle and highest risk for 
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ACL injury and laxity during the ovulatory phase (days 12-14) of the menstrual cycle.7 It 
was suggested that the use of HCs may reduce this risk due to their effects on suppressing 
follicular development and ovulation.7 Depending on their hormonal concentrations, HCs 
may play a role in suppressing ovulation, thus, altering female sex hormonal output, and 
decreasing risk for ligamentous knee laxity and injury. 
Hormones and ligamentous physiology. With increasing levels of estrogen, 
there is a significant decrease in collagen synthesis (40%) and fibroblast proliferation to 
the ACL.28 Additionally, estrogen is a vasodilator, which increases the permeability of 
the blood vessels, thus increasing the water content to the ACL.29 This creates a 
circulatory disruption in the ACL that can has been show to increase laxity, thereby 
predisposing an athlete to injury. 29  
Estrogen also has a role in controlling the receptors of relaxin on the ACL, 
meaning that when there is an increase in estrogen, there is an increase in relaxin 
sensitivity on the ACL.14,29 When there is an upregulation in progesterone, there is an 
increase is secretion of relaxin which causes a softening in soft tissue structures in the 
female body.30 Altogether, the sex hormones, estrogen and progesterone, may have an 
effect on the hormone relaxin, thus, altering the physiological structure of the ACL and 
predisposing a female athlete to ligamentous knee injury.12,14,29,30 
Estrogen and progesterone. Evidence suggests that female sex hormones 
influence soft tissue structures of the body. Liu et al29 studied the primary 
immunolocalization of estrogen and progesterone target cells in the human ACL in 13 
women and four men ranging 18-79 years of age.29 Knee ligament specimens were taken 
from each subject and studied under a microscope. Their results showed the presence of 
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estrogen and progesterone receptors in the cells of the ACL.  Specifically, the estrogen 
and progesterone receptors were found in the cell walls of the blood vessels in the ACL, 
which have been shown to directly affect the metabolism of the cells in the blood vessel 
walls. 29 
The presence of these sex hormone receptors in the ACL suggest that with their 
fluctuations, in both males and females, may influence the risk of ACL injury. 29 
However, since estrogen and progesterone are present in both males and females, the 
explanation for the increased prevalence of ligamentous injuries and laxity in females 
cannot be concluded. 9,29,31 These findings suggest that estrogen and progesterone may 
have a role in increasing the secretion of other hormonal components of the endocrine 
system.       
Relaxin. Relaxin is a peptide hormone in the insulin superfamily that is regulated 
by progesterone and glucocorticoids.4,7,9,14,15 If there is an increase of progesterone or 
glucocorticoids, there is an effect on relaxin levels, creating a physiologic effect 
throughout the body.15 There is a fluctuation of hormones that occur in both pregnant 
women and non-pregnant women during their menstrual cycle.  
During pregnancy the placenta and decidua secrete relaxin,9,11,14,30,31 which 
softens the ligaments of the pelvic joints and the pubic symphysis to allow the expansion 
of the pubic symphysis, up to 10 mm, during labor to expand the birth canal for 
delivery.11,14,31 During the luteal phase of the menstrual cycle, the corpus luteum secretes 
relaxin-2 mimicking its effect of pregnancy on the body.11,14,31 Although, its effect is to 
mainly soften the pelvic structures to aid in labor and delivery, relaxin has been shown to 
have an effect on other musculoskeletal structures of the body.11,14,31 
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Relaxin has collagenolytic effects in its upregulation of collagenases, matric 
metalloproteinases, and tissue plasminogen activator (tPA).9,14,30,31 It has an effect on 
ligamentous structures as it reduces the density and organization of collagen bundles 
leading to changes and a decrease in total collagen synthesis and content.9,29,31 This 
creates an effect on the soft tissue structures of the body, such as the ACL, which can 
predispose an athlete to a non-contact ligamentous injury.9 Because relaxin has only been 
detected in female’s, it may explain the significant increase in ACL injuries in females 
during menstruation, as opposed to males.9 
The relaxin receptors on the ACL are controlled by estrogen.14,29 When there is an 
upregulation of estrogen, there is an increase in sensitivity of target organs, such as the 
ACL, in its response to relaxin.14,29  However, relaxin levels are also shown to have a 
relationship with progesterone.12 Heitz et al12 found an increase in ACL laxity with an 
increase in estrogen and progesterone throughout the menstrual cycle.12 Nose-Ogura et 
al11 found that there was an increase in relaxin levels during the menstrual cycle’s luteal 
phase (phase III)  in 63.2% of female athletes.11 During this phase, there is also an 
increase in both estrogen and progesterone, suggesting that progesterone and/or estrogen 
may have an effect on relaxin output. 11 
Relaxin and the female ACL. Dragoo et al31 studied relaxin receptors in the human 
ACL.31 Five females and five males underwent ACL reconstruction surgery where the 
ACL was harvested arthroscopically. The females answered questionnaires pertaining to 
their age, history of pregnancy, and their use of oral contraceptives and were given a 
pregnancy test. If the females were previously or currently pregnant or using oral 
contraceptives they were excluded from the study. The harvested ACL’s were stored and 
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examined for relaxin levels with results indicating no binding of relaxin on the male 
ACL’s but binding in the female ACL’s. It was suggested that, although both males and 
females have estrogen and progesterone in their bodies, only females have relaxin within 
their ACL’s which may explain the prevalence for higher injury rates in females over 
males.31 
Dragoo et al14 continued this work by examining the effect of relaxin on the 
female ACL in the animal model.14 They randomly assigned 12 female guinea pigs into 
three groups, relaxin (RLX), relaxin plus estrogen (R+E), and normal ACL negative 
control and positive transected ACL control. Guinea pigs were chosen because of their 
response to relaxin and having an ACL large enough for biomechanical analysis. Over a 
21-day period, the guinea pigs were administered hormonal dosages to reach a pregnancy 
level. The laxity of the ACL was tested on day 0 and day 21 by implanting radio-opaque 
markers in the femur and tibia of each leg and applying 22 N of force. The guinea pigs 
ACL’s were tested to determine the ultimate load before failure. After the 21 days of 
hormone treatment, the guinea pigs treated with RLX, R+E, and controls showed a mean 
of 40.4 N, 32.7 N and 64.1 N of maximal load to failure, respectively, however there was 
no statistical difference between the RLX and R+E groups.14 
This study suggests that anterior displacement of the tibia increased after 
hormonal treatment from pre-test to post-test, but not between groups.14 Whether the 
guinea pigs were treated with RLX or R+E, the results indicate increased laxity to the 
ACL over the three weeks of treatment, suggesting the hormonal treatment altered the 
structural integrity of the female ACL. The data also showed the synergistic effect of 
R+E in that with the increase in estrogen there was an increase in relaxin. However, the 
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R+E group results were not significant compared to the RLX. This lack of significance 
confirms that the presence of relaxin is responsible for a majority of the biomechanical 
effect with ACL injury.14 
         Dragoo et al9 furthered their investigation by studying the correlation between 
relaxin and ACL tears among elite collegiate female athletes over a four year period.9 
The purpose was to study if elite female collegiate athletes with elevated serum relaxin 
concentrations (SRC) were at an increased risk of ACL injuries compared to those with 
lower SRC. National Collegiate Athletic Association (NCAA) Division I female athletes 
participating in basketball, lacrosse, field hockey, soccer, gymnastics and volleyball were 
included in this study. Participants were excluded if they were currently pregnant. All 
128 participants completed a questionnaire of their demographic information, menstrual 
history, pregnancy history, HC use, and ACL injury history. Urine tests were taken to 
determine the date of their LH surge. Blood tests revealed high levels of relaxin 
indicating subjects were in the mid-luteal phase of their menstrual cycle at the time of 
injury.9 
The results showed that 21.9% of the participants suffered ACL ruptures over the 
course of the four-year study. The mean SRC of those who tore their ACL was 6.0 ± 8.1 
pg/mL, and the mean SRC of those who did not tear their ACL was 1.8 ± 3.4 pg/mL. 
Those with a SRC greater than 6.0 pg/mL were four times as likely to injure their ACL 
than those with numbers below 6.0 pg/mL. However, since SRC peaks at the mid-luteal 
phase of the menstrual cycle, it is uncertain that the ACL collagen remodeling keeps up 
with this hormonal surge. It may be that exposure to high SRC’s over long time periods 
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increases the activation of relaxin receptors and is the possible cause of a decrease in 
ligament integrity during the menstrual cycle.9 
Dragoo et al30 examined the effect of HCs on SRC levels throughout the 
menstrual cycle in Division I female athletes.30 The 169 participants that participated in 
this study recorded their demographic information, menstrual history, pregnancy history, 
and HC use. Similar to their previous study4, urine tests were taken to determine the 
surge in LH and blood draws were taken in the mid-luteal phase so that the levels of SRC 
could be compared to menstrual history and HC use. It was reported that females taking 
HCs had lower levels of relaxin and progesterone than those not taking them. This can be 
described by the mechanism of action in that HCs have been reported to suppress of 
ovulation and sex hormones during the menstrual cycle. This study also suggests that 
progesterone may determine the levels of relaxin that are present during the menstrual 
cycle.30 
Hormonal contraception. HCs are hormones that can be taken orally, injected, 
implanted, inserted, or secreted into the female body.15,32 Females choose to use HCs for 
various reasons as they alter female sex hormones to manipulate the menstrual 
cycle.18,27,32,33 Because evidence suggests that female hormones create a physiological 
imbalance of the ACL and increases the risk for injury, HCs have been studied to 
determine their impact on ACL injury risk. 
When comparing HC users to HC non-users, a study suggests that there is an 
association between the use of HCs and ACL injury.7 There have been significant 
findings that HCs decrease the risk of ACL injury and knee laxity in female athletes.6.7 
The majority of this literature examines the use of commonly-used oral contraceptive 
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pills (OCP) compared to alternative HC methods. In one study, OCP use decreased the 
risk of ACL injury by 20% in female athletes, but it is unclear which type of OCPs were 
studied.7 There is limited evidence comparing the two classifications of HCs, progestin-
only versus estrogen+progesterone HC, and the different delivery modes of HCs. 
Classification. HCs can be classified into two categories, combined hormonal 
contraceptives (CHCs) of estrogen and progesterone, or progesterone-only contraceptives 
(POCs), all of which prevent ovulation using different mechanisms.18,27,32,33 Sixty-eight 
point five percent of female athletes use CHCs and 30% use POCs.18 Individually, both 
estrogen and progestin (progesterone) are able to inhibit follicle-stimulating hormone 
(FSH) and LH to suppress ovulation.32,33 Progestin blocks the midcycle rise in LH 
secretion causing it to inhibit ovulation.32,33 Ethinyl estradiol (estrogen) creates an 
increase in effectiveness of progestin to prevent irregular shedding of the 
endometrium.32,33 Together, CHCs (estrogen and progesterone combined) create a highly 
viscous cervical mucosa which causes an unsuitable environment for transportation and 
implantation of sperm.32,33  
In progestin-only contraceptives (POC), progestin creates a disruption in the 
hypothalamic-pituitary function, creating the suppression in ovulation. However, since 
the doses are lower in POCs contraceptives compared to CHCs there is higher chance of 
ovulation occuring.32 
Modes of delivery. There are subcategories of modes of delivery for both CHCs 
and POCs. HCs are determined for each individual female and their intended mechanism 
of use. The modes of delivery of HCs are oral pills, injections, transdermal patches, 
subdermal implants, intravaginal rings, and intrauterine devices.18,27 Oral contraceptives 
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are used the most by 78.4% of female athletes, followed by 13.1% implants, 3.8% 
injections, 2.8% IUDs, and 0.5% intravaginal rings.18 Oral contraceptive pills (OCP) have 
a first pass effect on the liver, meaning that it gets metabolized by the liver, and requires 
a greater dose of hormones.33 Other HCs bypass the liver, and require less doses of 
hormones.33 
         Oral contraceptive pills. Combined OCPs inhibit FSH and LH to prevent 
ovulation in the cervical mucosa and create changes in the endometrium to avoid 
implantation of sperm. 6,27,32 Combined OCPs generally consist of 21 active tablets and 
seven inactive tablets that are taken on a daily basis.27 However, this ratio can vary 
depending on the OCP being taken.27 The active tablets can consist of monophasic, 
biphasic, or triphasic formulas.27 The monophasic tablets consist of varying levels of 
estrogen and progesterone within each pill.27 The biphasic consist of two tablets of 
combinations of other hormones.27 Triphasic tablets are similar as they consist of 
combinations of other hormones, but in three tablets.27 These types of OCPs mimic the 
hormonal changes during the menstrual cycle.27 There is about 20-50 mg of estrogen and 
variations of the progesterone in the active tablets.27 POC pills, also known as 
“minipills”, are like OCPs, but contain low doses of progesterone only.27,32 
         Contraceptive injections. Contraceptive injections are a single 150 mg dose of 
medroxyprogesterone acetate (DMPA), a derivative of progesterone.27,32 DMPA’s 
mechanism of action is to suppress ovulation with the effects of the POCs.27,32 It is 
administered once every three months but has side effects which can include irregular 
bleeding at the onset of use, weight gain, and delay of fertility after cessation of 
injections. 27 
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         Transdermal patches. Transdermal patches consists of 150 mg of norelgesteromin 
(progestin) and 35 mg of ethinyl estradiol (estrogen).27 The patch is applied for the first 
three weeks of the menstrual cycle, then taken off for the last week of the menstrual 
cycle.27 Typically, it is placed on the abdomen, back, buttocks, or upper outer arm and 
can maintain itself through daily activities.27 Side effects can include headache, 
dysmenorrhea, breast discomfort, and local irritation at the application site.27 
         Subdermal implants. Subdermal implants consist of a 4 cm by 2 mm rod 
implanted into the body. Its mechanism of action is to partially suppress ovulation using 
the effects of the POCs.27,32 The rod has an inner ethylene vinyl acetate core surrounded 
by crystals containing etonogestrel, the active ingredient in progestin.27,32 Upon 
implantation, the implant releases 60-70 mg per day of progestin.27 That number is 
modified to 35-40 mg per day at the end of the first year, 30 mg per day at the end of the 
second year, and 40 mg per day at the end of the third year.27 The rod is surgically 
implanted and recommended to be removed at the end of three years of use.27 The most 
common side effect is irregular bleeding with the onset of use, however, there can also be 
changes in sex drive, weight gain, discoloration, or scarring of the skin over the implant, 
and pain or infection at the insertion site.27 
         Intravaginal rings. The intravaginal ring is a non-biodegradable, flexible, 
transparent device that is inserted into the vagina.27 It is similar to the transdermal patch 
as it is inserted for the first three weeks of the menstrual cycle and removed for the last 
week of the menstrual cycle.27 The intravaginal ring releases etonogestrel and ethinyl 
estradiol at a rate of 0.120 mg and 0.015 mg per day, respectively.27 
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         Intrauterine devices. Intrauterine devices (IUDs) are a POC method consisting of 
a T-shaped polyethylene frame with a steroid reservoir, containing a combination of 
levonorgestrel (progestin) and silicon, around the vertical stem.27 The device can hold 
either 13.5 mg or 52 mg of levonorgestrel that provides contraception for three or five 
years, respectively.27 
         Hormonal contraception and ligamentous knee injury. The regulation of 
hormones throughout the menstrual cycle has shown to create an effect on the integrity of 
the ACL.6 It has been suggested that these hormones are creating a risk factor for female 
athletes. However, HCs can potentially decrease this risk with its direct effect on the 
menstrual cycle with the hormones that it secretes into the body.6 CHCs, specifically, 
OCPs, contain set levels of estrogen and progesterone.6 These inhibit pituitary FSH and 
LH to prevent ovulation.6 Hence, it may have an effect on ligamentous structure and 
laxity. 
Hormonal contraceptive users versus hormonal contraception nonusers. 
Martineau et al6 studied ligamentous laxity in users of the OCP as compared to nonusers 
of the OCP.6 Female varsity athletes at an institution underwent a KT-1000 passive 
anterior translation measurement during their preseason physical examination. A 
screening questionnaire was completed to identify exclusion criteria. It asked about the 
use of OCP, and if so, the type of OCP, pregnancy history, and previous or present use of 
hormone-containing or hormone-altering products. Passive anterior translation of the tibia 
was measured with the KT-2000 Arthrometer at 67 N and 89 N.6 
         There were 78 participants in this study. Forty-two were OCP users and 36 were 
non OCP users. The results showed that the mean anterior translation of the tibia on the 
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non-dominant leg at 67 N of force was 3.00 ± 1.04 mm in OCP users and 3.86 ± 1.72 mm 
in non OCP users. The mean anterior translation of the tibia on the non-dominant leg at 
89 N of force was 3.98 ± 1.13 mm in OCP users and 4.83 ± 1.82 mm in non OCP users. 
These results were statistically significant, indicating that the OCP users had reduced 
knee laxity compared to non OCP users.6 This suggests that OCP use may not increase 
knee laxity in female athletes, thus, decreasing their risk of ligamentous knee injury. 
         Rahr-Wagner et al26 investigated women who underwent ACL reconstruction and 
their use of oral contraceptives (OC) over a six-year period.26 Included were 4,497 cases 
and the researchers matched each with at least one control. The OC use among women in 
both groups was investigated and the women were identified as either “never users,” 
(those who had no OC prescriptions throughout the study period) and “ever users” (those 
who had greater than or equal to one OC prescription throughout the study period).34 OC 
use was further examined by exploring how many years each case and control used it, 
with each subject rated as using it 1, 2 ,3, 4, or >4 years. They found that the “ever users” 
had a 11-20% decrease in risk of suffering an ACL injury that required surgery when 
compared to “never users”. However, the length of OC use did not have an effect on ACL 
injury risk.26 This means that those women who suffered an ACL injury that required 
operative treatment and were on an OC, despite the amount of time on it, were at a 
decreased risk for ACL injury compared to those not on an OC. 
         Ruedl et al34 studied menstrual cycle phase and OC use in recreational skiers who 
suffered non-contact ACL injuries.34 Over two winter seasons, subjects were recruited 
from a ski clinic where they underwent magnetic resonance imaging (MRI) for diagnosis 
of an ACL tear. Ninety-three subjects were included and were matched with 93 controls. 
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The subjects were given a questionnaire that recorded demographic information, history 
of knee injuries, menstrual cycle information, and the use of OC. The researchers found 
that OC use did not have an effect on decreasing the risk for ACL injury.34   
Hicks-Little et al2 also used the KT-100 knee arthrometer to assess anterior tibial 
displacement throughout the menstrual cycle stages and those who were using and not 
using HCs at the time of the study.2 Fifty-three female athletes with at least one healthy 
knee and a normal menstrual cycle were included. The average of two anterior tibial 
displacement measurements were taken on day 1, 13, and 23 of the menstrual cycle in 
conjunction with the three phases. The results showed that the subjects using HCs had 
increased laxity of the knee compared to subjects not using HCs.2 The researchers did not 
assess or indicate which types or modes of delivery of HCs were being used. These 
results suggest that HC use for the decrease in knee laxity is inconsistent throughout the 
literature. 
Conclusion. Female athletes have been shown to have greater amount of 
ligamentous knee laxity and greater risk for ligamentous knee injury compared to males. 
There are various risk factors that contribute to this with hormonal risk factors being one 
of them. Hormonal fluctuations that occur during the menstrual cycle may contribute to 
an increased risk of sustaining a ligamentous knee injury and hormonal contraceptive 
may reduce this risk, however, further research is needed on these matters.  
Statement of the Problem 
There is evidence suggesting that hormonal changes present during the menstrual 
cycle have an association with ligamentous knee injury. However, the data on the 
relationship between hormonal contraceptive use and ligamentous knee injuries among 
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female athletes is inconsistent. Also, there is limited evidence on the relationship between 
the types and modes of delivery of hormonal contraceptives and the risk of ligamentous 
knee injury. 
Aims and Hypotheses 
The purpose of this study is to determine the relationship between hormonal 
contraceptive (HC) use, and the type and severity of the injury sustained among female 
collegiate athletes who experience a ligamentous knee injury. It is hypothesized that there 
will be a relationship between the use of hormonal contraceptives and type and severity 
of ligamentous knee injury among female collegiate athletes who experience them. 
Specific hypotheses. Specific objective 1 is to identify the types of ligamentous 
knee injuries that are sustained by female collegiate athletes. 
         Specific hypothesis 1 is that there will be a greater number of anterior cruciate 
ligament injuries (ACL) compared to lateral collateral ligament (LCL), medial collateral 
ligament (MCL), and posterior cruciate ligament (PCL) injuries in female collegiate 
athletes who sustain a ligamentous knee injury. 
         Specific objective 2 is to identify in which phase of the menstrual cycle female 
collegiate athletes are at most risk for a ligamentous knee injury. 
         Specific hypothesis 2 is that female collegiate athletes in the luteal phase of the 
menstrual cycle will have the greatest number of ligamentous knee injuries compared to 
those in the follicular phase and ovulatory phase of the menstrual cycle. 
         Specific objective 3 is that among female athletes who sustain ligamentous knee 
injuries, determine the number who use combined-hormonal contraceptives (CHCs) 
versus progestin-only contraceptives (POCs). 
21 
 
Specific hypothesis 3 is that among female collegiate athletes who sustain a 
ligamentous knee injury, a greater number will report using progestin-only contraceptives 
versus combined hormonal contraceptives (CHCs). 
         Specific objective 4 is that among female collegiate athletes who sustain a 
ligamentous knee injury, determine the number who use hormonal contraceptives versus 
those who do not. 
         Specific hypothesis 4 is that among female collegiate athletes who sustain a 
ligamentous knee injury, there will be a greater number who are hormonal-contraceptive 
users compared to hormonal contraceptive non-users. 
         Specific objective 5 is to identify the types of hormonal contraceptives that female 
collegiate athletes are using when sustaining a ligamentous knee injury. 
         Specific hypothesis 5 is that there will be a greater number of female collegiate 
athletes who sustain a ligamentous knee injury who are users of oral contraceptive pills 
(OCP) compared to those who use intravaginal rings, transdermal patches, subdermal 
implants, and injections.  
 Specific objective 6 is that among female collegiate athletes who have had a 
ligamentous knee injury, determine the relationship between hormonal contraceptive use 
and type of ligamentous knee injury sustained.  
 Specific hypothesis 6 is that the use versus non-use of hormonal contraceptives 
among female athletes who sustain a ligamentous knee injury will not be associated with 
the type of injury sustained. 
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Specific objective 7 is that among female collegiate athletes who have had a 
ligamentous knee injury, determine the relationship between hormonal contraceptive use 
and severity of the ligamentous knee injury. 
Specific hypothesis 7 is that the use of hormonal contraceptives among female 
athletes who sustain a ligamentous knee injury will be associated with a less severe 
injury.  
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Chapter 2 
Manuscript 
Abstract 
Context: Female athletes are three to six times more likely than males to sustain a 
ligamentous knee injury due to hormonal risk factors. Hormones of the menstrual cycle 
have been shown to alter the physiological component of ligamentous structures during 
the three phases of the cycle. Use of hormonal contraceptives (HCs) may influence the 
incidence and severity of ligamentous knee injuries in female athletes. 
Objective: To determine the relationship between HC use and the type and severity of 
knee ligament injuries sustained among female collegiate athletes. 
Design: Cross-sectional study. 
Setting: Online survey. 
Patients or Other Participants: Female National Collegiate Athletic Association 
(NCAA) athletes at least 18 years of age or older who experienced a ligamentous knee 
injury during the study time period (n=336). 
Data Collection and Analysis: Electronic survey assessed the type and severity of the 
ligamentous knee injury, body mass index, variables related to the menstrual cycle, and 
variables related to HC use. Chi-Square analyses were performed using SPSS version 26. 
Results: There were significant relationships between injury type and severity of injury 
(measured by days lost of participation) X2 (2, n=170)=40.9, p = 0.000, injury type and 
severity of injury X2 (8, n=170)=47.4, p=0.000, and injury type and menstrual cycle 
phase X2 (10, n=192)=43.397, p=0.000. A majority of respondents were using HCs. Most 
(37.9%) of the injuries occurred in the luteal phase of the menstrual cycle, where athletes 
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were more likely to sustain multiple ligament injuries. The type of ligamentous knee 
injury impacted the severity of the injury. 
Conclusions: Female athletes were at the greatest risk for ligamentous knee injury in the 
luteal phase of the menstrual cycle. Future work should aim to identify injury prevention 
programs, protective equipment, and HC for decreasing the risk for ligamentous knee 
injury. 
Key words: Female athletes, ligamentous knee injury, menstrual cycle, hormonal 
contraceptives. 
Introduction 
Since the passing of Title IX of the United States Education Assistance Act in 
1972, there has been a significant increase of female participation in athletics.1,2 In 
professional basketball, 60% more injuries occur in women as compared to men, with 
16% of these injuries being to the knee.5 Compared to male athletes, female athletes have 
a 20% increase in rotary knee laxity and a significantly higher score on the Landing Error 
Scoring System (LESS), placing them in a high-risk category.15 Collegiate female 
athletes account for approximately 67% of all anterior cruciate ligament (ACL) injuries 
and 69% of non-contact ACL injuries compared to their male counterparts, making 
females 3-6 times more likely than males to sustain an ACL injury.6,7,8,9,10 
Hormonal risk factors are one of the various underlying risk factors that can 
predispose an athlete to a ligamentous knee injury.9,13 Specifically, the menstrual cycle 
can increase the susceptibility of non-contact knee injuries in female athletes because of 
its constant fluctuation of hormones throughout the phases. 6,8,9,12,14 Wojtys et al25 found 
that the time frame females sustained ACL injuries was more likely to occur in the 
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ovulatory phase (phase II, days 10-14) of the menstrual cycle compared to the other 
phases.25 Heitz et al12 found the greatest amount of laxity in the luteal phase (phase III, 
days 15-28) of the menstrual cycle.12 Hertzberg et al7 found that there was an increased 
risk of ACL injury during the ovulatory phase (phase II, days 12-14) of the menstrual 
cycle.7 
Estrogen and progesterone have been shown to have receptors on the ACL in both 
males and females.29 However, only females are reported to produce relaxin. This 
hormone which is controlled by estrogen and progesterone alters collagen synthesis to 
soften soft tissue structures during pregnancy and phase III of the menstrual 
cycle.9,11,14,29,30 This physiological alteration can predispose a female athlete to a 
ligamentous knee injury. Dragoo et al14 found an increase in anterior tibial displacement 
after the treatment of estrogen and relaxin in an animal model.14 In a different study, 
Dragoo et al9 found that female athletes with elevated serum relaxin concentrations 
(SRC) were four times as likely to tear an ACL than those with lower SRC.9  
The literature assessing the use of hormonal contraceptives (HCs) in decreasing 
the risk of ligamentous knee injury in females is inconsistent. Martineau et al6 studied 
oral contraceptive pill (OCP) use in female athletes and found a greater decrease in knee 
laxity in OCP users compared to OCP non-users.6 Rahr-Wagner et al26 found a 11-20% 
decrease in risk of sustaining an ACL injury in HC users compared to non-users.26 Ruedl 
et al34 reported that OCP use has no effect on decreasing ACL injury risk.34 Hicks-Little 
et al2 concluded that users of HC have an increase in laxity compared to HC non-users.2 
Also, there is no published evidence on the relationship between the types and modes of 
delivery of HCs and the risk of ligamentous knee injury.   
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The purpose of this study is to determine the relationship between hormonal 
contraceptive use and the type and severity of the injury sustained among female 
collegiate athletes who sustain ligamentous knee injuries. We hypothesize that there will 
be a relationship between the use of hormonal contraceptives and both type and severity 
of ligamentous knee injury in female collegiate athletes who have these injuries. 
Methods 
         Participants. We emailed NCAA athletic trainers from Division I, II and III 
institutions with a link to an electronic survey to share with female athletes at their 
institutions who were competing during the fall 2019/winter 2019 season and sustained a 
ligamentous knee injury. 
Inclusion criteria. Female collegiate athletes participating in athletics at NCAA 
institutions were included in this study. They were at least 18 years of age, sustained a 
ligamentous knee injury (ACL, MCL, PCL, LCL) in their fall 2019/winter 2019 sport 
season (August 1, 2019 – December 31, 2019), had at least one day’s loss of athletic 
participation, and were evaluated by an athletic trainer or diagnosed by physician as 
having a ligamentous knee injury. 
Exclusion criteria. Eligible participants were excluded if one or more of the 
following criteria were present: currently pregnant, had a previous procedure of a 
hysterectomy or tubal ligation, used an IUD at time of injury, used a hormonal treatment 
that is not considered hormonal contraception (example: testosterone) at the time of 
injury, and/or did not identify as a female. 
Pregnant female collegiate athletes were excluded because their hormonal levels 
are different from those of non-pregnant athletes throughout the monthly cycle. Female 
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collegiate athletes who have had a hysterectomy (removal of the uterus) or tubal ligation 
(blockage of the fallopian tubes) were also excluded because they do not menstruate and 
may be on a hormonal treatment other than hormonal contraceptives (HCs).  Females 
who use IUDs were also excluded, as they are typically women who already have 
children. They are likely to have hormonal levels that are unlike the traditional-aged, 
childless female collegiate athletes. In addition, most IUDs do not contain any hormones. 
Since the purpose of this study was to investigate the potential impact of hormonal 
contraception, it was not appropriate to include the IUD user in the group of participants. 
         Procedures. We created an electronic survey using the Qualtrics Survey Software 
system (Provo, UT). Consent was obtained from the eligible participants electronically 
before starting the survey (Appendix A). We utilized the National Athletic Trainers’ 
Association’s (NATA) Research and Education Foundation’s resources to distribute the 
surveys to NCAA athletic trainers nationally, reaching 4,389 athletic trainers. Data were 
collected between August 20, 2019 and December 31, 2019. Additional materials (i.e: 
personal letter and flyers) were used to recruit participants (Appendix B). This study was 
reviewed and approved by the researcher’s University Institutional Review Board (IRB), 
Study ID: Pro2019000511. 
         Survey. The online survey consisted of a total of 26 questions related to exclusion 
criteria (stated above), demographic information (age, sex, height, weight, division, and 
sport), ligamentous knee injury characteristics (date the injury was sustained, type of 
injury, mechanism, and playing surface), menstrual cycle characteristics (on menstrual 
cycle at time of sustaining the injury and dates of last 3 menstrual cycles), and HC use 
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(use at the time of injury, mode of delivery, name, milligram contents, and menstruation 
frequency) (Appendix A).   
 Menstrual cycle phase calculation.  We calculated the menstrual cycle phase for 
each participant by counting the number of days between the date that the participant’s 
ligamentous knee injury occurred and the date of her most recent menstrual cycle. For the 
15 participants who did not list both dates, we made an assumption that their menstrual 
cycles were 28 days long and calculated the date of the start of their menstrual cycle after 
their knee injury.  We excluded 21 participants who did not indicate that they 
menstruated monthly.  
For the 168 participants who provided usable data, the menstrual cycle phase was 
categorized as either “Follicular”, “Ovulatory”, “Luteal” or “Over 35 days” (Table 1). 
 
 
 
Table 1 
Menstrual Cycle Phases 
Menstrual Cycle Phase Number of Days into the Menstrual Cycle 
Follicular 0-9 
Ovulatory 10-14 
Luteal 15-35 
Over 35 days Greater than 35 
 
 
 
Data analysis. All data analyses were completed using SPSS v.26 (IBM SPSS, 
Inc. Chicago, IL). Descriptive statistics were calculated for each variable. Means and 
standard deviations were identified for age, height, weight, and body mass index. Next, 
we conducted a series of Chi-Square analyses to determine the significance of the 
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relationships between key variables. First, we explored the relationship between HC use 
(users vs. non-users) and type of ligamentous injury sustained (single vs. multiple 
ligament injury). Second, we analyzed the relationship between HC use and the severity 
of the ligamentous knee injury sustained (as reflected by the number of days’ 
participation lost due to the injury). Third, we examined the relationship between the type 
of ligamentous knee injury and the severity, as measured by days of participation loss. 
Fourth, we examined the relationship between menstrual cycle phase and injury type.   
 We ran t-tests to compare the means of BMI for athletes with single versus 
multiple ligament injuries. We explored the relationships between BMI and injury type 
using both t-tests and a one-way ANOVA. 
Results 
         Response rate. A total of 336 of these athletes completed the survey.  We could 
not calculate the response rate because we did not know how many female athletes 
sustained a ligamentous knee injury and how many of them were asked by their athletic 
trainer to complete the survey. After exclusion criteria were applied to the data, a total of 
212 responses were eligible for use in analyses. 
         Demographic and injury characteristics. We identified the demographic and 
injury characteristics of the 212 respondents (Table 2).  The mean age of the respondents 
was 20 ± 1.193 years. Division III collegiate female athletes sustained more ligamentous 
knee injuries than any other division (39.6%). Injuries were also highest among women’s 
soccer players (60.9%), through a non-contact mechanism (65.6%), and on an artificial 
grass (turf) playing surface (41.4%). The majority of respondents (74.5%) lost 29 days or 
more of athletic participation time loss (Table 2). 
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Of the 192 ligamentous knee injuries sustained by the respondents, more than half 
(61.5%) of the injuries were characterized as an ACL tear alone and 23.4% ACL injuries 
occurred in conjunction with an injury to another ligamentous structure of the knee 
(Table 2). There were 142 (74%) respondents who had a single ligament involvement, 
compared to 47 (24.5%) respondents who had multiple ligament involvement. The 
remaining 3 respondents were unsure what their injury was, and we characterized them as 
“unknown”. Approximately, 75% of the respondents lost 29 or more days of athletic 
participation (Table 2). 
 
 
 
Table 2 
Demographic and Injury Characteristics of Respondents  
Variable (out of N respondents of each variable) n (%) 
Age in years (N = 212)  
18 41 (19.3) 
19 40 (18.9) 
20 60 (28.3) 
21 58 (27.4) 
22 11 (5.2) 
Greater than 22 2 (0.9) 
Division (N = 192)  
Division I 67 (34.9) 
Division II 49 (25.5) 
Division III 76 (39.6) 
Sport (N = 192)  
Women’s soccer 117 (60.9) 
Women’s basketball 28 (14.6) 
Women’s indoor volleyball 16 (8.3) 
Women’s lacrosse 11 (5.7) 
Other 20 (10.4) 
Mechanism (N = 192)  
Contact 66 (34.4) 
Non-contact 126 (65.6) 
Playing surface (N = 192)  
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Table 2 (continued)  
Variable (out of N respondents of each variable) n (%) 
Artificial grass 79 (41.4) 
Grass 56 (29.2) 
Gymnasium floor 49 (25.5) 
Other 8 (4.2) 
Type of ligamentous knee injury (N = 192)  
ACL 118 (61.5) 
ACL + LCL 4 (2.1) 
ACL + LCL + MCL 4 (2.1) 
ACL + MCL 31 (16.1) 
ACL + PCL 1 (0.5) 
ACL + PCL + MCL 3 (1.6) 
ACL + PCL + MCL + LCL 1 (0.5) 
LCL 1 (0.5) 
LCL + MCL  2 (1) 
MCL  21 (10.9) 
PCL 2 (1) 
PCL + MCL  1 (0.5) 
Unknown 3 (1.6) 
Type of ligamentous knee injury (N = 192) 
 
 
Single ligament 142 (73.9) 
Multiple ligaments 47 (24.5) 
Unknown 3 (1.6) 
Days loss of athletic participation (N = 212)  
Up to 7 13 (6.1) 
Up to 14  15 (6.6) 
Up to 21 14 (6.1) 
Up to 28  12 (5.7) 
29 or more 158 (74.5) 
 
 
 
 
Menstrual cycle and hormonal contraceptive use characteristics. We report 
the data on menstrual cycle and HC use in Table 3. Approximately 70% of the 
participants did not recall being on the menstrual cycle when sustaining their ligamentous 
knee injury. The majority (37.9%) of the participants were in the luteal phase of the 
menstrual cycle at the time of injury.  
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More than half (60.4%) of the respondents were using a HC at the time of injury 
while the rest were not on a HC (39.6%). Of the HC users, 87.7% were using a combined 
hormonal contraceptive (CHC) vs. 12.5% using a progestin-only contraceptive (POC). 
87.7% of respondents that were using an OCP at the time of sustaining their ligamentous 
knee injury. More than half of the respondents did not answer the questions pertaining to 
the classification of their HC, which may limit these findings. 
 
 
 
Table 3 
Menstrual Cycle and Hormonal Contraceptive Usage Characteristics 
Variable (out of N respondents of each variable) n (%) 
On menstrual cycle at time of injury (N = 192)  
Yes 41 (21.4) 
No 132 (68.8) 
I don’t remember 19 (9.9) 
Menstrual Cycle Phase (N = 190)  
Follicular 56 (29.5) 
Ovulatory 25 (13.2) 
Luteal 72 (37.9) 
Over 35 days 15 (7.9) 
Unknown 22 (11.6) 
Hormonal Contraceptive Use (N = 192)  
Yes 116 (60.4) 
No 76 (39.6) 
Hormonal Contraceptive Mode of Delivery (N = 114)  
Oral Pill 100 (87.7) 
Subdermal implant 9 (7.9) 
Injection 3 (2.6) 
Intravaginal ring 2 (1.8) 
Transdermal patch 0 (0) 
Hormonal Contraceptive Classification (N = 104)  
Combined hormonal contraceptive (CHC) 91 (87.5) 
Progestin-only contraceptive (POC) 13 (12.5) 
Menstruation Frequency (N = 98)  
Every month 75 (76.5) 
Every 2 months 2 (2) 
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Table 3 (continued) 
Variable (out of N respondents of each variable) n (%) 
Every 3 months  6 (6.1) 
Never 10 (10.2) 
Other 5 (5.1) 
 
 
 
Results of Chi-Square analyses. Chi-Square analyses showed no significance 
between ligamentous knee injury type and any of the following variables: HC use, 
playing surface, type of sport played, BMI or menstrual cycle phase (Table 4).  
Injury type when characterized as the top three injuries. There was a statistically 
significant relationship between ligamentous knee injury type (when categorized as the 
top three injuries: ACL, ACL+MCL, and MCL) and the severity of the ligamentous knee 
injury (as measured by days’ participation loss) X2 (2, N = 170) = 40.9, p = 0.000 (Table 
4). Injuries involving the ACL (ACL alone or ACL+MCL) were significantly more likely 
to result in a loss of 29 days or more when compared to injuries of the MCL alone. This 
was further demonstrated when we collapsed the severity categories to just two (less than 
29 days or greater than or equal to 29 days) X2 (8, N = 170) = 47.4, p = 0.000 (Table 4). 
 
 
 
Table 4 
Injury Type Chi-Square Analyses (when categorized as top three injuries: ACL, 
ACL+MCL, and MCL) 
 
Variables Df Value p 
Hormonal contraceptive use 2 0.751 0.687 
Playing surface  
All categories 
Artificial grass/turf, grass, 
gymnasium floor, other 
 
6 
18 
 
2.337 
12.917 
 
0.886 
0.796 
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Table 4 (continued) 
Variables Df Value p 
Sport 
All sports 
Women’s soccer vs. other 
 
2 
16 
 
1.268 
13.919 
 
0.530 
0.605 
Menstrual cycle phase 10 9.586 0.478 
Severity 
5 categories 
2 categories 
 
2 
8 
 
40.9 
47.4 
 
*0.000 
*0.000 
*statistical significance (p < 0.05)    
 
 
 
Injury type as single versus multiple ligament injuries. Chi-Square analyses 
showed no significant relationships between the amount of ligament involvement (single 
versus multiple) and the following variables: severity, type of sport played, HC users vs. 
non-users, division, HC type, BMI, and playing surface (Table 5).  There was a 
statistically significant relationship between the amount of ligament involvement and 
menstrual cycle phase X2 (10, N = 192) = 43.397, p = 0.000 (Table 5). For both single and 
multiple ligament injuries, athletes were most likely to be in the luteal phase of the 
menstrual cycle. This was especially true for athletes with multiple ligament injuries. 
 
 
 
Table 5 
Injury Type Chi-Square Analyses (when categorized as single versus multiple ligament 
injury) 
 
Variables Df Value p 
Hormonal contraceptive use 1 0.363 0.547 
Playing surface  
All categories 
Artificial grass/turf, grass, 
gymnasium floor, other 
 
9 
3 
 
5.960 
4.013 
 
0.744 
0.874 
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Table 5 (continued) 
Variables Df Value p 
Sport 
All sports 
Women’s soccer vs. other 
 
8 
1 
 
5.429 
0.025 
 
0.711 
0.874 
Severity 
5 categories 
2 categories 
 
4 
1 
 
3.960 
0.901 
 
0.411 
0.342 
Division 2 0.088 0.957 
Hormonal contraceptive type 2 0.578 0.749 
Mode of delivery 5 1.481 0.915 
Menstrual cycle phase (5 categories, 
see table 3) 
10 43.397 *0.000 
*statistical significance (p < 0.05)    
 
 
 
Results of t-test and one-way ANOVA. We ran an independent samples t-test to 
explore the relationship between BMI and the two levels of injury, single versus multiple. 
The results did not show significance between the means [t (186) = -0.165, p = 0.869)]. 
We also ran a one-way ANOVA to explore the relationship between BMI and three levels 
of injury type. This result was also non-significant [F (2,166) = 0.051, p = 0.950]. 
Discussion 
 The purpose of this study was to determine the relationship between hormonal 
contraceptive use and the type and severity of the injury sustained among female 
collegiate athletes who sustain a ligamentous knee injury. We hypothesized that there 
would be a relationship between the use of hormonal contraceptives and type and severity 
of ligamentous knee injury among female collegiate athletes who experience them. Our 
specific hypotheses examined the type of ligamentous knee injuries sustained, which 
phase of the menstrual cycle the injury was sustained, the types of hormonal 
contraceptives that were used, the number of respondents who were hormonal 
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contraceptive users vs. non-users, modes of delivery of the hormonal contraceptives, and 
severity of the ligamentous knee injuries.   
 Type of injury sustained. Anterior cruciate ligament (ACL) injuries were the 
most commonly injured ligament structure of the knee (84.4%), regardless if it was 
isolated or combined with another ligamentous injury, thus supporting our first 
hypothesis. It commonly occurred in isolation (61.5%) rather than combined with another 
ligamentous structure of the knee (22.9%). Previous research by Anderson et al10 has 
reported a 67% occurrence rate of ACL injuries among female athletes, although it is 
unknown how many structures were involved in these cases.10  
 Medial collateral ligament (MCL) were the second most frequent injury type in 
this study, at 10.9% for isolated and 21.9% for combined ligament injury, resulting in a 
total occurrence prevalence of 32.8%. This is slightly higher than the reported 26-29% 
occurrence rate of MCL injuries in other studies.21,23  
 Both lateral collateral ligament (LCL) and posterior cruciate ligament (PCL) 
occurred in 6.25% and 4.16% of the cases in this study, respectively. Both were slightly 
higher than previously reported occurrences of 2-4% in other studies.21,23 They both were 
most commonly associated with another knee ligament injury. 
 Severity of injury sustained. Respondents who had an ACL or ACL+MCL 
ligamentous knee injury were more likely to have 29 or more days of athletic 
participation loss compared to an MCL alone ligament injury. Therefore, if the ACL is 
involved in the ligamentous knee injury, there is a greater chance of missing more 
playing time as compared to other ligamentous structures of the knee. The ACL plays a 
large role in stabilizing the knee by preventing anterior translation and rotation of the 
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tibia and the MCL stabilizes the medial knee by preventing valgus motion.22 Surgical 
intervention is often determined for MCL injuries dependent on the grade of the injury.36 
Grades I and II typically heal with conservative treatment, while grade III may need 
surgical intervention depending on its response to non-operative treatment or if it is 
combined with another ligamentous structure, such as the ACL, that requires operative 
treatment.36 Since the ACL has a large role in stabilizing the knee22, when it is damaged it 
may needs surgical intervention to be repaired to allow for normal gait. 
 Menstrual cycle phase. Ligamentous knee injuries occurred most often during 
the luteal phase of the menstrual cycle at 37.9%, supporting our second hypothesis. Our 
results confirm the prior findings of  Heitz et al12, who found that the greatest amount of 
ACL laxity occurred in the luteal phase of the menstrual cycle.12 However, there were 
only seven subjects included in their study and ACL laxity was measured, not ACL 
injury risk or surveillance of ACL injury. Wojtys et a25 found that 15 women suffered a 
non-contact ACL injury in the follicular phase, 28 in the ovulatory phase, and 22 in the 
luteal phase of the menstrual cycle.25 Also, Hertzberg et al7 found that females were at 
the lowest risk of ACL injury in the luteal phase of the menstrual cycle and the highest 
risk of ACL injury in the ovulatory phase of the menstrual cycle.7 Although our results 
showed that the greatest amount of ligamentous knee injury occurred in the luteal phase 
of the menstrual cycle, there was less than a 10% difference between injuries that 
occurred in the luteal phase and injuries that occurred in the follicular phase of the 
menstrual cycle.  
This study hypothesized an increase in ACL injury rates due to the reported 
increase in hormone levels during the menstrual cycle’s luteal phase. During this phase, 
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both estrogen and progesterone spike and fluctuate throughout.7,8,15,25,27 Also, relaxin 
levels increase and peak during this phase in 63.2% of female athletes.9,11 This may cause 
a hormonal imbalance and predispose the knee to ligamentous injury. It is important to 
note that each menstrual cycle phase is different in length of days, and that the luteal 
phase may be associated with more injuries simply because it is longer than the others 
and not because of hormonal differences. While we cannot change the time length for 
each phase, we interpret our statistical analyses using the variable menstrual cycle phase 
with this confounder in mind. 
The second greatest occurrence of ligamentous knee injury was in the follicular 
phase of the menstrual cycle, which could be for two reasons. One being that the 
follicular phase is the second largest time frame of the three menstrual cycle phases 
following the luteal phase and more injuries would occur during this compared to the 
ovulatory phase. Second, this could be explained by the theory that ACL collagen 
remodeling may not keep up with the hormonal surges that occur during the luteal phase 
of the menstrual cycle and may not present with the ligamentous knee injury until a later 
time.9. It may be that exposure to high serum relaxin concentrations over long periods of 
time increases the activation of relaxin receptors and is the possible cause in ligament 
integrity during the menstrual cycle.9 
Single vs. multiple ligament involvement. We found the highest number of 
multiple and single ligament injuries occurring in the luteal phase of the menstrual cycle, 
especially multiple ligament injuries. This coincides with our second hypothesis that 
there would be a greater number of ligamentous knee injuries in the luteal phase of the 
menstrual cycle compared to the follicular and ovulatory phases. While there was not a 
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large difference between the number of ligamentous knee injuries that occurred within 
each menstrual cycle phase, our findings of a greater occurrence of multiple ligament 
injuries during the luteal phase makes our hypothesis and findings especially true. Not 
only were the respondents more likely to sustain a ligamentous knee injury during the 
luteal phase, they were also more likely to sustain multiple ligament knee injuries. 
However, further research is needed to strengthen the literature on this topic. 
 Hormonal contraceptive use. 
 Types of HC used. Over 80% of our respondents were using a CHC compared to 
a POC. This does not support our third hypothesis that among female collegiate athletes 
who sustain a ligamentous knee injury, a greater number will report using POCs versus 
CHCs. We based our hypothesis off the literature that CHCs contain doses of both 
estrogen and progestin and in return can control both of these sex hormone fluctuations 
(estrogen and progesterone) that occur during the menstrual cycle. Therefore, POCs only 
control for progestin and we believed that with estrogen not being controlled in the POC 
users there would be a greater amount of injuries. However, CHCs tend to be more 
commonly used because they are better tolerated than POCs due to fewer negative side 
effects.13 In our study, 87.5% of female athletes reported using CHCs, which is higher 
than the prevalence reported by Martin18 (68.5%) of CHCs used by female athletes.13 We 
determined the type of HC used by determining the milligram contents of the HCs 
reported by respondents in the survey, which may have resulted in some inaccuracy due 
to the nature of self-reported data. 
Hormonal contraceptive users versus non-users. Our fourth hypothesis was also 
supported by the data, which showed a greater number of HC users (60.4%) than non-
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users (39.6%) among this population. This is greater than what Martin18 previously 
reported (49.5%).18 These results may be due to the multiple mechanisms of action of 
HCs, such as the contraceptive effect and decreasing the symptoms associated with 
dysmenorrhea.6,7 This can work in favor of competitive female athletes by decreasing the 
likelihood of missing playing time.19 It is worth noting that the reason for HC use was not 
assessed in the participants of our study.  
Type of injury sustained. We did not find any significant associations between the 
HC users and non-users and the type of injury sustained, which supports our sixth 
hypothesis. There is limited evidence on this because most of the literature assessed 
either the ACL only or other structures of the body, such as the patellar tendon and 
achilles tendon.35 As for ACL injury assessment, Ruedl et al19 concluded that HC use, 
specifically OCPs, had no effect on decreasing the risk for ACL injury.19 Further research 
is needed on assessing injuries of all ligamentous structures of the knee and their 
association with the use vs. non-use of HCs.  
Severity of injury sustained. Last, we did not find any significant associations 
between the use of hormonal contraceptive and a less severe injury, which does not 
support our seventh hypothesis. Although, we did find that those who had the ACL 
involved in their ligamentous knee injury had a greater severity or time loss from 
participation, this was not associated with the use or non-use of hormonal contraceptives 
and more literature is needed on this matter.  
 Modes of delivery. The most common HC mode of delivery in HC users was the 
OCP at 87.7% compared to alternative modes of delivery at 12.3%, which supports our 
third hypothesis. This is greater than what was previously reported at 78.4% by Alentorn-
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Geli et al.13 Competitive female athletes favor OCPs compared to other modes of delivery 
because of their ability to manipulate menstruation.11 Schaumberg et al11 reported a 
significant difference in menstruation manipulation planning in competitive athletes 
compared to sub-elite recreationally active women.11 Alternative modes of delivery 
(subdermal implants, injections, intravaginal rings, and transdermal patches) may be used 
less often than OCPs because they are administered/ implanted by either a doctor or have 
a preset number of hormones to secrete dependent on the menstrual cycle and in return 
cannot be used to manipulate the menstrual cycle.27 This can also cause inconvenient in-
house doctor visits causing more frequent co-pays. 
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Chapter 3 
Conclusions, Future Work, and Limitations 
Conclusions 
 Overall, we found that there were significant relationships between injury type 
and severity, and between injury type and stage of the menstrual cycle for ligamentous 
knee injuries sustained in NCAA female collegiate athletes. There were a greater number 
of respondents who were HC users compared to HC non-users. Of the HC users, the 
majority of the respondents were using CHCs and OCPs. The results suggest that 
ligamentous knee injuries sustained by the respondents occurred in the luteal phase 
(phase III) of the menstrual cycle.  Likewise, respondents were more likely to sustain 
multiple ligament injuries compared to single ligament injuries during this phase. 
Additionally, the type of ligamentous knee injury, specifically injuries involving the ACL 
(ACL and ACL+MCL), resulted in a more severe injury (greater amount of days loss of 
athletic participation).  
 It would be unrealistic and problematic to instruct female athletes to reduce the 
intensity of their activity during certain stages of the menstrual cycle. Although, it was 
not assessed in this study, future work could aim to research prevention programs and 
compare different types of equipment/bracing for the prevention of ligamentous knee 
injuries in female athletes.  
Future Work 
 The present study only included female athletes who sustained a ligamentous 
knee injury. Future research should prospectively monitor a large sample of female 
athletes, including those who do and do not sustain a ligamentous knee injury, to 
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determine potential differences between the two groups and identify HC use factors 
associated with sustaining a ligamentous knee injury.   
Additionally, future research should recruit subjects who use CHCs and POCs in 
equal numbers, allowing for meaningful comparisons of ligamentous knee injury factors 
between the two groups. Also, future research should aim to compare female athletes 
who use various types of HCs to female athletes who do not use any form of HCs to 
determine if HCs decrease the risk of ligamentous knee injury.  
Limitations 
 A limitation of our study was that the responses of the survey were self-reported 
from the participants. Self-reported data carries the risk of inaccuracy of the responses 
due to the challenge of accurately recalling details pertaining to the time of injury, 
misunderstanding questions, or intentionally misrepresenting the responses to questions. 
This may have skewed the results as respondents may have estimated the dates of their 
menstrual cycle and injury, had to remember if they were on their menstrual cycle or not 
at the time of injury, and may have misinterpreted directions given when providing HC 
information. This could be avoided if non-injured female athletes were recruited before 
the start of their sport season and given directions on keeping a record of their menstrual 
cycle dates, date of injury if they sustain one during the study time period, and HC use 
information.  
We shared the survey with athletic trainers to administer to appropriate 
participants and is considered a strength because the athletic trainer may know and 
understand better than the injured athletes the details of the injury, however, a second 
limitation was that we could not calculate the response rate. We do not know how many 
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athletic trainers shared the survey with their injured female athletes and then how many 
of those female athletes actually completed the survey. Knowing a response rate would 
strengthen our study but may not skew the study or our results in a direction if the 
respondents answered truthfully.  
A third limitation to our study is that the time period was consistent with the fall 
and partial winter seasons but did not extend to the remaining winter and spring seasons. 
An extension of the time period may provide more respondent characteristics that could 
be used for analyses.  
Last, menstrual cycle phase is defined in days, with each of the three phases 
lasting a different number of days. It is possible that the statistical analyses performed 
with this variable were affected by the varying time frame of each phase. This is a 
limitation of the present study. In future studies, a more sophisticated statistical analysis 
could potentially correct for this confounder. 
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Appendix A 
Survey 
Consent 
Welcome to the research study!   
TITLE OF STUDY:  The relationship between the use of hormonal contraceptives and 
ligamentous knee injury in the female collegiate athlete 
Principal Investigator: Dr. Leslie Spencer 
  
*You are being asked to take part in a research study. This consent form is part of an 
informed consent process for a research study and it will provide key information that 
will help you decide whether you wish to volunteer for this research study.  
*Please carefully read the introductory information provided below.  They will provide 
clear information about the purpose of the study, study specific information about what 
will happen during the study, what are the anticipated risks and benefits, and what 
alternatives are available to you if you do not wish to participate in this research study. 
*The study team will explain the study to you, and they will answer any question you 
might have before volunteering to take part in this study. It is important that you take 
your time to make your decision. *You may take this consent form with you to ask a 
family member or anyone else before agreeing to participate in the study. 
*If you have questions at any time during the research study, you should feel free to ask 
the study team and should expect to be given answers that you completely understand. 
*After all your questions have been answered, if you still wish to take part in the study, 
you will be asked to give your informed consent at the bottom of this form. 
*You are not giving up any of your legal rights by volunteering for this research study or 
by signing this consent form. 
  
1. What is the purpose of the study? 
The purpose of this study is to determine the relationship that hormonal 
contraceptives have with ligamentous knee injury in female collegiate athletes. 
  
2. Why have you been asked to take part in this study? 
You have been asked to take part in this study because you are at least 18 years of 
age, a female, a NCAA student-athlete, have sustained at least one ligamentous 
knee injury recently, and have lost at least one day of athletic participation. 
  
3. What will you be asked to do if you take part in this research study? 
If you decide to take part in this research study, you will be asked to complete a 
series of questions on an electronic survey. Questions included in the survey will 
be related to your demographic information, menstrual cycle, ligamentous knee 
injury, and hormonal contraceptive use, if applicable. 
  
4. Who may take part in this research study?  And who may not? 
50 
 
Participants may be included if they are at least 18 years of age, or older, female, 
NCAA student-athletes, have sustained at least one ligamentous knee injury 
between the period of August 1st, 2019 – December 31st, 2019, and have at least 
one day's loss of athletic participation due to their ligamentous knee injury. 
Participants will be excluded if they are males, under the age of 18 years, non-
NCAA athletes, have not sustained a ligamentous knee injury, have no day’s loss 
of athletic participation, are currently pregnant, have undergone a hysterectomy 
(previous removal of the uterus), have undergone a tubal ligation (tying of the 
fallopian tubes), are on a hormonal treatment of testosterone, or have an 
intrauterine device (IUD) inserted in them. 
  
5. How long will the study take and where will the research study be 
conducted? 
The study will take approximately 5-15 minutes to complete. It may be done from 
an electronic device, such as, but not limited to, a laptop/computer, tablet, or 
smartphone. 
  
6. How many visits may take to complete the study?  
This study can be completed in one sitting. 
  
7. What are the risks and/or discomforts you might experience if you take part 
in this study? 
There is absolutely no physical risk of harm for you in this study. There may be 
mild psychological/ emotional risk when asking you to recall factors that relate to 
possible mild, moderate, and severe ligamentous knee injuries. 
 
8. Are there any benefits for you if you choose to take part in this research 
study? 
There may not be any direct benefit. However, there may be mild benefits for the 
participants in this study as the study may suggest hormonal risk factors that 
relate to previous ligamentous knee injury. There may be benefits to female 
collegiate athletes in the future on how to reduce the risk of ligamentous knee 
injuries. 
 
9. What are the alternatives if you do not wish to participate in the study? 
Your alternative is not to participate in this study. 
  
10. How many subjects will be enrolled in the study? 
We anticipate approximately 200 responses 
  
11. How will you know if new information is learned that may affect whether 
you are willing to stay in this research study? 
Given that this is a one-time survey and you do not provide your identity and 
contact information, it will not be possible to follow-up with you individually. If 
new information about the topic is learned during the course of the study, an 
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email will be sent to all of the Athletic Trainers who received the initial invitation 
to participate.  
  
12. Will there be any cost to you to take part in this study? 
There is not cost for you to take part in this study. 
  
13. Will you be paid to take part in this study? 
You will not be paid for your participation in this research study. 
  
14. Are you providing any identifiable private information as part of this 
research study? 
No. This a completely anonymous survey. 
  
15. How will information about you be kept private or confidential? 
The information you provide will never be associated with your personal identity. 
The survey is anonymous. 
Data will be stored electronically in a password protected program on a computer 
and backed up to a flash drive. The principle investigator, associate investigator, 
and committee members will be the only personnel with access to the data. The 
data will be kept and stored electronically on the hard drive of the Principal 
Investigator for three years, after which, the data will be permanently deleted.  
  
16. What will happen if you do not wish to take part in the study or if you later 
decide not to stay in the study? 
Participation in this study is voluntary. You may choose not to participate, or you 
may change your mind at any time. 
If you do not want to enter the study or decide to stop participating, your 
relationship with the study staff will not change, and you may do so without 
penalty and without loss of benefits to which you are otherwise entitled. 
  
17. Who can you call if you have any questions? 
If you have any questions about taking part in this study or if you feel you may 
have suffered a research related injury, you can call the Principal 
Investigator:         
Dr. Leslie Spencer 
School of Health Professions | Health and Exercise Science Department 
856-256-4500 ext. 53761 | spencer@rowan.edu 
 
If you have any questions about your rights as a research subject, you can call: 
Office of Research Compliance 
(856) 256-4078– Glassboro/CMSRU 
  
18. What are your rights if you decide to take part in this research study? 
You have the right to ask questions about any part of the study at any time.  You 
should not sign this form unless you have had a chance to ask questions and have 
been given answers to all your questions. 
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AGREEMENT TO PARTICIPATE 
I have read the entire information about the research study, research risks, benefits and 
the alternatives, or it has been read to me, and I believe that I understand what has been 
discussed.  
All my questions about this form or this study have been answered and I agree to 
volunteer to participate in the study.  
o I consent, begin the study 
o I do not consent, I do not wish to participate 
Skip To: End of Survey If Q1 = I do not consent, I do not wish to participate 
 
 
Agreement of Age 
Display This Question: 
If Q1 = I consent, begin the study 
I am at least 18 years of age or older 
o Yes   
o No   
Skip To: End of Survey If  = No 
 
Survey 
Q1 Are you currently pregnant? 
o Yes   
o No   
Skip To: End of Survey If Q1 = Yes 
 
Q2 Have you ever had a hysterectomy (removal of the uterus)? 
o Yes   
o No   
Skip To: End of Survey If Q2 = Yes 
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Q3 Have you ever had a tubal ligation (fallopian tubes tied)? 
o Yes   
o No   
Skip To: End of Survey If Q3 = Yes 
 
Q4 Do you currently use an intrauterine device (IUD)? 
o Yes   
o No   
Skip To: End of Survey If Q4 = Yes 
 
Q5 Are you currently on a hormonal treatment that is not considered hormonal 
contraception (for example: testosterone)? 
o Yes  
o No   
 
Skip To: End of Survey If Q5 = Yes 
Q6 How old are you? 
o less than 18   
o 18   
o 19   
o 20   
o 21    
o 22    
o greater than 22   
Skip To: End of Survey If Q6 = less than 18 
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Q7 Do you identify as female? 
o Yes   
o No   
Skip To: End of Survey If Q7 = No 
 
Q8 Are you currently an NCAA athlete? 
o Yes   
o No   
Skip To: End of Survey If Q8 = No 
 
Q9 Have you recently sustained a ligamentous knee injury? 
o Yes   
o No   
Skip To: End of Survey If Q9 = No 
 
Q10 How many days of athletic participation have you lost due to your ligamentous knee 
injury? 
o 0 days    
o 1-7 days   
o 1-14 days   
o 1-21 days   
o 1-28 days   
o 29+ days   
Skip To: End of Survey If Q10 = 0 days 
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Q11 How tall are you? 
 30 37 44 51 58 65 72 79 86 93 100 
 
Inches () 
 
 
Q12 How much do you weigh? 
 100 120 140 160 180 200 220 240 260 280 300 
 
Pounds () 
 
 
Q13 What division is the institution you play for? 
o Division I    
o Division II  
o Division III   
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Q14 What sport do you currently play? 
▼ Women's basketball (1) ... Women's indoor volleyball (21) 
 
Q15 When did you sustain your ligamentous knee injury? 
o Date (mm/dd/yyyy)  _______________________________________________ 
 
Q16 What is the name of the ligamentous knee injury you recently sustained? (check all 
that apply) 
▢ Anterior cruciate ligament (ACL) sprain/tear    
▢ Posterior cruciate ligament (PCL) sprain/tear   
▢ Grade I lateral collateral ligament (LCL) sprain   
▢ Grade II lateral collateral ligament (LCL) sprain   
▢ Grade III+ lateral collateral ligament (LCL) sprain   
▢ Grade I medial collateral ligament (MCL) sprain    
▢ Grade II medial collateral ligament (MCL) sprain    
▢ Grade III+ medial collateral ligament (MCL) sprain   
▢ I do not know  
▢ Other ________________________________________________ 
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Q17 Was the cause of your ligamentous knee injury a contact or non-contact 
mechanism?  
Contact- another person or object causing a direct blow to your knee 
Non-contact- no other outside forces caused your knee to injure 
o Contact   
o Non-contact  
 
Q18 What playing surface were you playing on when sustaining your ligamentous knee 
injury? 
o Artificial grass / turf   
o Grass   
o Gymnasium floor   
o Track   
o Sand   
o Concrete / road   
o Wooden bowling ally   
o Synthetic bowling ally   
o Other   ________________________________________________ 
 
Q19 Were you having your menstrual period at same time you sustained your 
ligamentous knee injury? 
o Yes   
o No   
o I don't remember   
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Q20 What are the dates of the start of your last three menstrual cycles? Please take your 
best guess if you are not certain. 
o Last menstrual cycle date (mm/dd/yyyy)   
________________________________________________ 
o Second to last menstrual cycle date (mm/dd/yyyy) 
________________________________________________ 
o Third to last menstrual cycle date (mm/dd/yyyy) 
________________________________________________ 
 
Q21 Were you taking a hormonal contraceptive (hormonal birth control) at the time you 
sustained your ligamentous knee injury? 
o Yes   
o No    
Skip To: End of Survey If Q21 = No 
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Q22 What is the mode of delivery of your hormonal contraceptive? 
o Oral pill   
o Intravaginal ring   
o Transdermal patch   
o Subdermal implant   
o Injection   
o Other  ________________________________________________ 
 
Q23 What is the name of your hormonal contraceptive? 
o Alesse-28  
o Apri  
o Aviane  
o Brevicon  
o Crysella  
o Demulen 1/35-21  
o Demulen 1/35-28  
o Demulen 1/50-21  
o Demulen 1/50-28  
o Desogen  
o Estrostep 21  
o Estrostep FE  
o Genora 1/35  
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o Genora 1/50  
o Jenest 28  
o Junel Fe 20  
o Kariva  
o Levlite 28  
o Levlen 21  
o Levlen 28  
o Levora 0.15/30-21  
o Levora 0.15/30-28  
o Lo Estrin 24-4  
o Loestrin 21 1/20  
o Loestrin 21 1.5/30  
o Loestrin fe 1/20  
o Loestrin fe 1.5/30  
o Lo-Ovral 28  
o Low-Ogestrel 28  
o Lutera  
o Microgestin 1/20  
o Microgestin 1.5/30  
o Microgestin fe 1/20  
o Microgestin fe 1/5/30  
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o Micronor  
o Mircette  
o Modicon  
o Mononesessa  
o Necon 0.5/35-21  
o Necon 0.5/35-28  
o Necon 1/50-21  
o Necon 1/50-28  
o Necon 1/35-21  
o Necon 1/35-28  
o Necon 10/11-21  
o Necon 10/11-28  
o Nor-QD  
o Nordette 28  
o Norinyl 1/50  
o Norinyl 1/35  
o Nortrel 0.5/35  
o Nortrel 1/35  
o Ogestrel 0.5/50-28  
o Ortho-cept  
o Ortho-Novum 1/35  
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o Ortho-Novum 1/50  
o Ortho-Novum 10/11  
o Ortho-Novum 7/7/7  
o Ortho-cyclen  
o Ortho Tri-Cyclen  
o Ortho Tri-Cyclen LO  
o Ovcon 50  
o Ovcon 35  
o Ovral 28  
o Ovrette  
o Seasonale  
o Seasonique  
o Sprintec  
o Tri-Levlen 21  
o Tri-Levlen 28  
o Tri-Norinyl 28  
o Trinessa  
o Triphasil 28  
o Tri-Sprintec  
o Trivora 28  
o Yasmin 28  
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o Yaz  
o Zovia 1/50E  
o Zovia 1/35E  
o NuvaRing  
o Kyleena  
o Liletta  
o Mirena  
o Skyla  
o Ortho Evra  
o Xulane  
o Implanon  
o Nexplanon  
o Norplant  
o Depo Provera  
o Other ________________________________________________ 
 
 
Display This Question: 
If Q23 = Other 
Q24 If you selected "other", please provide the name of your hormonal contraceptive 
below: 
________________________________________________________________ 
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Q25 What are the milligram levels in your hormonal contraceptive? Please reference the 
examples below of where to find this on your hormonal contraceptive packaging. The 
first set of images are examples of where to find the values for estrogen. The second set 
images are examples of where to find values for progesterone. If there is only ONE 
number provided, please insert "0" for "Estrogen" and that provided number for 
"Progesterone".   
    
*Note: Estrogen may be referred to as Ethinyl Estradiol or others.    
*Note: Progesterone may be referred to as Norelgestromin, Norethidrone acetate, 
etonogestrel, etc. 
o Estrogen   ________________________________________________ 
o Progesterone   ________________________________________________ 
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Q26 How often do you menstruate when taking your hormonal contraceptive? 
o Every month   
o Every 2 months   
o Every 3 months   
o Every 6 months   
o Other   ________________________________________________ 
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Appendix B 
Subject Recruitment 
Cover Letter 
You are invited to participate in a survey titled “The relationship between the use of 
hormonal contraceptives and ligamentous knee injury in the female collegiate athlete.” 
The study is being conducted by Leslie Spencer, Ph.D., Shari Willis, Ph.D., Robert 
Weaver, Ph.D., and Nicole Thompson, Athletic Training student, of Rowan University, 
School of Health Professions, Health and Exercise Science Department, 201 Mullica Hill 
Road, Glassboro, New Jersey 08028.  
 
The purpose of this study is to determine the relationship that the use of hormonal 
contraceptives have with ligamentous knee injury in female collegiate athletes. The 
estimated time it will take to complete this survey is 5-15 minutes.  
 
There is absolutely no physical risk of harm to participants in this study. There may be 
mild psychological / emotional risk in asking you, the participant, to recall factors that 
relate to a mild, moderate, or severe ligamentous knee injury. 
 
There may not be benefits to the individual participants in this study. There may be 
benefits to female collegiate athletes in the future on how to reduce the risk of 
ligamentous knee injuries.  
 
We are collecting private information in this research study. Your identifiable 
information will not be used in any of the future research projects or disclosed to anyone 
outside of the research team. Data will be stored electronically in a password protected 
program on the hard drive of the University-issued computer of the Principal Investigator 
and backed up to a flash drive. The Principal Investigator, student investigator, and two 
thesis committee members will be the only personnel with access to the data. Your 
privacy and confidentiality will be protected. There will be no use of names with data 
being stored electronically. The data will be kept and stored confidentially on the hard 
drive of the Principal Investigator for three years after the conclusion of the study. At that 
point, the electronic data will be completely erased. Hard copies of the data will not be 
kept.  
 
Your participation in this study is voluntary. You may withdraw from the study at any 
point of time. If you have any questions or concerns related to this study, you may 
contact the investigators listed.  
 
Nicole Thompson 
Athletic Training student, 
Rowan University 
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Thompsonn3@students.rowan.edu 
856-812-1689 
 
Leslie Spencer, Ph.D. 
Professor of Health and Exercise Science 
Rowan University  
spencer@rowan.edu  
856-256-4500 ext. 53761 
 
This study has been reviewed and approved by the Rowan University Institutional 
Review Board. If you have any questions about your rights as a participant or are 
dissatisfied at any time with any aspect of this study, you may contact the Office of 
Research Compliance at (856) 256-4078.  
 
IRB Approval Number: Pro2019000511 
 
If you agree to participate, please follow the link below and take the survey. Otherwise, 
you may exit out of the survey. 
 
Thank you.  
 
 
To complete the survey, click on link below: 
________________________________________ 
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Flyer  
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Personal Letter 
Hello, 
 
My name is Nicole Thompson and am a fifth-year athletic training student at Rowan 
University in Glassboro, New Jersey. Currently, I am working toward obtaining my 
master’s in athletic training and am studying female collegiate athletes and hormonal risk 
factors that may be associated with ligamentous knee injuries as my thesis project. 
Previously, a survey has been sent out to athletic trainers to share with their ligamentous 
knee injured female athletes to assess these factors. Unfortunately, the response rate has 
been low, and I would appreciate it if you could cooperate with the study team and I by 
distributing the link to this survey link below out to eligible participants with the 
following criteria: 
• Female NCAA athlete 
• At least 18 years of age, or older 
• Prognosed (by you) or diagnosed (by a D.O. or M.D.) to have sustained a 
ligamentous knee injury (ACL, MCL, LCL, and/or PCL) in the 2019 fall or the 
2019 winter season 
• At least one day loss of athletic participation 
 
Female collegiate athletes who have met the inclusion criteria above are eligible to 
complete this short survey. It will take approximately 5-15 minutes and can be completed 
on an electronic device. If possible, please assist me in sharing the survey to appropriate 
athletes at your institution.  
 
If you or your athletes have any questions or concerns regarding this study, please do not 
hesitate to reach out to me or my faculty advisor. Our contact information is listed below. 
Thank you for your time. 
 
Nicole Thompson 
Rowan University ‘20 
Athletic Training 
Thompsonn3@students.rowan.edu 
(856) 812-1689 
 
Leslie Spencer, Ph.D. 
spencer@rowan.edu 
856-256-4500 ext. 53761 
 
*Study has been approved by Rowan IRB, IRB# Pro2019000511 
 
 
